Besides the patent expiration reasons stated, it is apparent that the sales staff needs to be commensurate with market opportunities. The US is becoming a relatively stagnant Pharma market. I think NVS felt that a streamlined sales force could function fine and that global resources were best directed to faster growing markets.
Market Data 
Markets 
AI
